ADCT

ADC Therapeutics SA: Q1 2026 Financial Summary

Business Context and Reporting Period

This summary covers the unaudited quarterly results for ADC Therapeutics SA (ADCT) for the period ended March 31, 2026. ADC Therapeutics is a commercial-stage biopharmaceutical company focused on antibody-drug conjugates (ADCs), primarily commercializing ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company operates as a single reportable segment and is classified as a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Total revenue decreased 9.5% to $20.9 million. While product revenue from ZYNLONTA increased 15.1% to $20.0 million due to higher volume and pricing, license revenues and royalties dropped 85.5% to $0.8 million. This decline was driven by the absence of a one-time $5.0 million milestone payment recognized in Q1 2025 related to Health Canada approval.
• Operating Expenses: Total operating expenses decreased 10.5% to $46.1 million.
  • R&D Expenses: Decreased 31.3% to $19.9 million, primarily due to the 2025 Restructuring which discontinued early-stage solid tumor programs and reduced workforce by ~30%.
  • Selling & Marketing: Increased 20.4% to $12.7 million, driven by higher marketing spend and personnel costs for commercial fulfillment.
  • Cost of Product Sales: Increased 75.4% to $3.6 million, largely due to a shift of personnel costs from R&D to commercial manufacturing and higher shipping/storage charges.
• Other Income/Expense: "Other, net" income increased significantly to $2.6 million (from $0.2 million) due to a $2.2 million gain from the change in fair value of warrant obligations issued to HealthCare Royalty Management (HCR).

Guidance, Outlook, and Risks

• Liquidity: Management believes current cash resources ($231.0 million) are sufficient to fund operations for at least the next 12 months. The company plans to fund operations through cash on hand, ZYNLONTA revenues, and potential future financing.
• Strategic Focus: The company is advancing ZYNLONTA into earlier lines of therapy (LOTIS-5 and LOTIS-7 trials) and indolent lymphomas. It is also developing a PSMA-targeting ADC.
• Debt and Financing:
  • HCR Amendment: In February 2026, the company amended its royalty purchase agreement with HCR, reducing the change-of-control payment obligation from $750 million to $150 million (if occurring before end of 2027). In exchange, the company issued warrants to purchase ~9.8 million shares.
  • Term Loan: The senior secured term loan carries an effective interest rate of 15.87%. Principal payments began in 2026.
• Risks: Key risks include the need for additional capital, uncertainties in clinical trial outcomes, reliance on third-party manufacturers, and the impact of the HCR agreement on future cash generation and acquisition attractiveness.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $231 million cash balance against the ~$30 million quarterly operating cash burn and upcoming debt principal payments.
• HCR Warrant Impact: Assess the dilution risk and fair value volatility associated with the 9.8 million warrants issued to HCR in February 2026.
• Revenue Quality: Confirm the sustainability of the 15% product revenue growth given the significant drop in royalty income and the one-time nature of the prior year's milestone.
• Restructuring Benefits: Monitor whether the 30% workforce reduction and program discontinuations continue to yield the projected R&D savings in subsequent quarters.
• Debt Covenants: Review the restrictive covenants associated with the Oaktree/Owl Rock term loan and the HCR agreement to ensure compliance.